Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
37.25
+1.06 (2.93%)
At close: Apr 17, 2026, 4:00 PM EDT
37.50
+0.25 (0.67%)
After-hours: Apr 17, 2026, 6:52 PM EDT
Cogent Biosciences Employees
Cogent Biosciences had 258 employees as of December 31, 2025. The number of employees increased by 53 or 25.85% compared to the previous year.
Employees
258
Change (1Y)
53
Growth (1Y)
25.85%
Revenue / Employee
n/a
Profits / Employee
-$1,274,950
Market Cap
6.00B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 258 | 53 | 25.85% |
| Dec 31, 2024 | 205 | 41 | 25.00% |
| Dec 31, 2023 | 164 | 26 | 18.84% |
| Dec 31, 2022 | 138 | 61 | 79.22% |
| Sep 30, 2022 | 121 | 44 | 57.14% |
| Dec 31, 2021 | 77 | 62 | 413.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Rhythm Pharmaceuticals | 414 |
| Mirum Pharmaceuticals | 372 |
| Xenon Pharmaceuticals | 370 |
| Scholar Rock Holding | 289 |
| Celcuity | 155 |
| CG Oncology | 142 |
COGT News
- 2 days ago - Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 18 days ago - Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 4 weeks ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - GlobeNewsWire
- 7 weeks ago - Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 3 months ago - These 20 stocks are strong choices for momentum investors - Market Watch